Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) – Stock analysts at HC Wainwright issued their FY2023 earnings per share estimates for Madrigal Pharmaceuticals in a research note issued on Monday, November 13th. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will post earnings of ($19.47) per share for the year. HC Wainwright currently has a “Buy” rating and a $275.00 target price on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($19.30) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q4 2023 earnings at ($5.18) EPS, Q1 2024 earnings at ($5.39) EPS, Q4 2024 earnings at ($3.33) EPS, FY2024 earnings at ($18.08) EPS, FY2025 earnings at $1.06 EPS and FY2026 earnings at $28.92 EPS.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($5.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.90) by ($0.44).
Madrigal Pharmaceuticals Stock Up 7.2 %
MDGL stock opened at $156.47 on Wednesday. The company has a current ratio of 2.36, a quick ratio of 2.36 and a debt-to-equity ratio of 5.16. The firm has a 50 day simple moving average of $149.32 and a 200-day simple moving average of $204.37. The company has a market capitalization of $3.09 billion, a P/E ratio of -8.13 and a beta of -0.70. Madrigal Pharmaceuticals has a twelve month low of $57.21 and a twelve month high of $322.67.
Institutional Investors Weigh In On Madrigal Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDGL. Bradley & Co. Private Wealth Management LLC raised its stake in shares of Madrigal Pharmaceuticals by 307.4% in the 1st quarter. Bradley & Co. Private Wealth Management LLC now owns 110 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 83 shares in the last quarter. Garda Capital Partners LP bought a new stake in shares of Madrigal Pharmaceuticals in the 1st quarter worth approximately $34,000. Exchange Traded Concepts LLC acquired a new stake in Madrigal Pharmaceuticals during the second quarter valued at approximately $39,000. Montag A & Associates Inc. boosted its holdings in Madrigal Pharmaceuticals by 223.3% during the third quarter. Montag A & Associates Inc. now owns 194 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 134 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new position in shares of Madrigal Pharmaceuticals in the first quarter valued at $55,000. Institutional investors own 79.86% of the company’s stock.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH.
- Five stocks we like better than Madrigal Pharmaceuticals
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Boeing’s future sealed as China resumes order flow
- What Is Dividend Yield and How Do You Calculate It?
- Your best bets into China’s race for EV takeover
- Earnings Per Share Calculator: How to Calculate EPS
- Fisker Inc. price implosion; is it time to buy the dip?
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.